GlassScriptPhysician profile
Heather Cummings
NPI 1902283526
$7,828.05
in general payments reported to CMS, 2019-2025
33 companies · $3,547 in 2025
The $3,547 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $629 · 2023: $1,595 · 2024: $1,829 · 2025: $3,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,885 · Education: $86.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,884.72 |
| Education | $86.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,433.16 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $929.41 | 2021-2025 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $788.08 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $569.82 | 2021-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $551.46 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $447.24 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $327.30 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $314.87 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $273.51 | 2024-2025 | Iqirvo |
| Genzyme Corporation | $225.66 | 2023-2024 | |
| Gilead Sciences, INC. | $209.46 | 2022-2025 | |
| Novo Nordisk INC | $206.68 | 2025 | Wegovy |
| Celgene Corporation | $206.13 | 2022-2024 | Zeposia |
| Pfizer INC. | $182.99 | 2023-2025 | |
| Lilly USA, LLC | $144.38 | 2024-2025 | Omvoh |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $144.29 | 2022-2023 | |
| Madrigal Pharmaceuticals | $139.99 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $108.92 | 2025 | Givlaari |
| Celltrion USA INC. | $101.59 | 2025 | Vegzelma |
| Ferring Pharmaceuticals INC. | $93.28 | 2022-2025 | Rebyota |
| Ironwood Pharmaceuticals, INC | $69.72 | 2021-2024 | Linzess |
| Daiichi Sankyo INC. | $60.22 | 2025 | Injectafer |
| Braintree Laboratories, INC. | $50.98 | 2021-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $46.16 | 2025 | |
| Merck Sharp & Dohme LLC | $35.12 | 2022 | |
| Medtronic, INC. | $27.10 | 2025 | Pillcam |
| Sandoz INC. | $26.62 | 2023 | Hyrimoz |
| Aimmune Therapeutics, INC. | $24.56 | 2024 | |
| Shield Therapeutics INC | $21.64 | 2025 | |
| Redhill Biopharma INC. | $21.54 | 2024 | Talicia |
| Alexion Pharmaceuticals, INC. | $16.63 | 2022 | |
| Albireo Pharma, INC. | $15.72 | 2022 | |
| Evoke Pharma, INC. | $13.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Cummings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.